Dr. Ferran J. García

Abnormally Low Antibody Markers of Elastin Synthesis in Patients with Fibromyalgia Syndrome

Journal of Musculoskeletal Pain (ISSN: 1058-2452,)Volume: 14 Issue: 3, (2006), Page Range: 13 - 19

DOI: 10.1300/J094v14n03_03

Keith K. Colburn MD, John A. Rambharose MD, Marilyn C. Malto BS, Stephan Baydanoff PhD, Lawrence B. Sandberg MD, PhD, Lora M. Green PhD.

Keith K. Colburn MD, Chief of Rheumatology, Medical-111R & Research Service-151, Jerry L. Pettis Memorial Veteran Medical Center, Loma Linda, CA, 92350, Esta dirección de correo electrónico está protegida contra los robots de spam, necesita tener Javascript activado para poder verla John A. Rambharose MD, Department of Rheumatology, Loma Linda University School of Medicine, Loma Linda, CA, 92354 Marilyn C. Malto BS, Department of Rheumatology, Loma Linda University School of Medicine, Loma Linda, CA, 92354 Stephan Baydanoff PhD, Professor and Chairman, Department of Biology, Pleven, Pleven, Bulgaria Lawrence B. Sandberg MD, PhD, Professor, Microbiology & Biochemistry, Loma Linda University Graduate School, Loma Linda, CA, 92354 Lora M. Green PhD., Molecular Immunologist, Department of Rheumatology, Loma Linda University School of Medicine, Loma Linda, CA, 92354,

CONCLUSIONES: se detectaron variaciaciones en el metabolismo de la elastina en pacientes con Fibromialgia. Esta alteración en el metabolismo de la elastina ocurre en términos de una reducción de la producción de elastina en pacientes de fibromialgia. La relación entre el metabolismo de la elastina y la patologia de la enfermedad esta actualmente siendo investigada.

Abnormally Low Antibody Markers of Elastin Synthesis in Patients with Fibromyalgia Syndrome

Journal of Musculoskeletal Pain (ISSN: 1058-2452,)Volume: 14 Issue: 3, (2006), Page Range: 13 - 19

DOI: 10.1300/J094v14n03_03

Keith K. Colburn MD, John A. Rambharose MD, Marilyn C. Malto BS, Stephan Baydanoff PhD, Lawrence B. Sandberg MD, PhD, Lora M. Green PhD.

Keith K. Colburn MD, Chief of Rheumatology, Medical-111R & Research Service-151, Jerry L. Pettis Memorial Veteran Medical Center, Loma Linda, CA, 92350, Esta dirección de correo electrónico está protegida contra los robots de spam, necesita tener Javascript activado para poder verla John A. Rambharose MD, Department of Rheumatology, Loma Linda University School of Medicine, Loma Linda, CA, 92354 Marilyn C. Malto BS, Department of Rheumatology, Loma Linda University School of Medicine, Loma Linda, CA, 92354 Stephan Baydanoff PhD, Professor and Chairman, Department of Biology, Pleven, Pleven, Bulgaria Lawrence B. Sandberg MD, PhD, Professor, Microbiology & Biochemistry, Loma Linda University Graduate School, Loma Linda, CA, 92354 Lora M. Green PhD., Molecular Immunologist, Department of Rheumatology, Loma Linda University School of Medicine, Loma Linda, CA, 92354,

Background: Antibodies [Abs] to tropoelastin [elastin precursor] and alpha-elastin [elastin breakdown product] are found in serum of all human subjects and correlate with their respective serum peptide levels; however, peptide levels vary with age and some disease states. This study was undertaken to determine if serum elastin Abs reflective of elastin metabolism were altered in patients with fibromyalgia syndrome [FMS] by determining the ratio of serum antitropoelastin to anti-alpha-elastin Ab levels.

Method: Serum samples from 20 female patients with FMS were compared with samples from 19 age-matched healthy normal control subjects for the levels of anti-elastin Abs directed against tropoelastin and alpha elastin using enzyme-linked immunosorbent assays.

Results: Anti-tropoelastin Abs in the sera of patients with FMS were decreased relative to the levels measured in healthy subjects [P < 0.0002].

The ratios of anti-tropoelastin to anti-alphaelastin Abs were 1.98 versus

1.01 for control and FMS subjects, respectively. This suggested a decrease in elastin production in patients with FMS. There were no differences in the average values of anti-alpha-elastin Abs in the FMS patients sera compared to the average value of the control samples, suggesting there was no differences in elastin destruction.

Conclusions: Variations in elastin metabolism were detected in sera of patients with FMS. This suggests an altered elastin metabolism in terms of reduced elastin production in patients with FMS. The relationship between elastinmetabolism and disease pathology is currently being explored.